SRTS logo

Sensus Healthcare, Inc. Stock Price

NasdaqCM:SRTS Community·US$57.1m Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 114 Fair Values set on narratives written by author

SRTS Share Price Performance

US$3.35
-1.45 (-30.21%)
US$5.75
Fair Value
US$3.35
-1.45 (-30.21%)
41.7% undervalued intrinsic discount
US$5.75
Fair Value
Price US$3.35
AnalystConsensusTarget US$5.75
AnalystHighTarget US$8.00
NateF US$13.42

SRTS Community Narratives

·
Fair Value US$5.75 41.7% undervalued intrinsic discount

Increased CMS Reimbursement And International Expansion Will Unlock Demand

2users have liked this narrative
0users have commented on this narrative
40users have followed this narrative
·
Fair Value US$8 58.1% undervalued intrinsic discount

Growing Global Aging Will Expand Noninvasive Treatment Markets

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Fair Value
·
Fair Value US$13.42 75.0% undervalued intrinsic discount

SRTS Market Outlook

6users have liked this narrative
0users have commented on this narrative
44users have followed this narrative
US$13.42
75.0% undervalued intrinsic discount
Fair Value
Revenue
20.39% p.a.
Profit Margin
22.54%
Future PE
12.76x
Price in 2030
US$18.35

Trending Discussion

Updated Narratives

SRTS logo

SRTS Market Outlook

Fair Value: US$13.42 75.0% undervalued intrinsic discount
44 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
SRTS logo

SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset

Fair Value: US$5.75 41.7% undervalued intrinsic discount
40 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
SRTS logo

SRTS: 2026 Reimbursement Codes And New Platform Rollout Will Drive Upside

Fair Value: US$8 58.1% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

1 Risk
2 Rewards

Sensus Healthcare, Inc. Key Details

US$22.5m

Revenue

US$14.0m

Cost of Revenue

US$8.5m

Gross Profit

US$16.3m

Other Expenses

-US$7.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.47
37.74%
-34.50%
0%
View Full Analysis

About SRTS

Founded
2010
Employees
60
CEO
Joseph Sardano
WebsiteView website
sensushealthcare.com

Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.

Recent SRTS News & Updates

Narrative Update May 19

SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset

Analysts have trimmed their price target on Sensus Healthcare from $6.88 to $5.75, citing revised fair value assumptions that factor in updated expectations for revenue growth, profit margins and a much higher future P/E multiple linked to anticipated demand for the SRT platform and new 2026 reimbursement codes. Analyst Commentary Recent research highlights both optimism and caution around Sensus Healthcare as analysts recalibrate their expectations and fair value work.

Recent updates

No updates